TITLE:
Treatment With SU11248 in Patients With Neuroendocrine Tumors

CONDITION:
Neuroendocrine Tumors

INTERVENTION:
Sunitinib

SUMMARY:

      To assess the safety and efficacy of SU11248 in patients with Neuroendocrine Tumors.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Histologically or cytologically proven diagnosis of carcinoid tumor or pancreatic
             islet cell tumor.

          -  Evidence of unidimensionally measurable disease as per Response Evaluation Criteria
             in Solid Tumors (RECIST).

          -  ECOG performance status 0 or 1

        Exclusion Criteria:

          -  Diagnosis of small-cell carcinoma, pheochromocytoma/paraganglioma, Merkel cell
             carcinoma, or any other second malignancy within the last 5 years except for
             adequately treated basal cell or squamous cell skin cancer, or for in situ carcinoma
             of the cervix uteri.

          -  Prior treatment with any tyrosine kinase inhibitors or anti-VEGF angiogenic
             inhibitors. Prior treatment with non-VEGF-targeted angiogenic inhibitors is
             permitted.
      
